TABLE OF CONTENTS
1 INTRODUCTION 22
1.1 OBJECTIVES OF THE STUDY 22
1.2 MARKET DEFINITION 22
1.3 OVERVIEW OF GLOBAL RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET 23
1.4 CURRENCY AND PRICING 24
1.5 LIMITATIONS 24
1.6 MARKETS COVERED 25
2 MARKET SEGMENTATION 28
2.1 MARKETS COVERED 28
2.2 GEOGRAPHICAL SCOPE 29
2.3 YEARS CONSIDERED FOR THE STUDY 30
2.4 CURRENCY AND PRICING 30
2.5 RESEARCH METHODOLOGY 31
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 34
2.7 SECONDARY SOURCES 35
2.8 ASSUMPTIONS 35
3 MARKET OVERVIEW 36
3.1 DRIVERS 37
3.1.1 INCREASING PREVALENCE OF SKIN DISEASE OR CONDITION 37
3.1.2 RISING AGING POPULATION 38
3.1.3 GROWTH IN TOPICAL DRUG DELIVERY 39
3.1.4 INCREASING RESEARCH AND DEVELOPMENT OF NEW DERMATOLOGICAL DRUGS 40
3.1.5 NEW PRODUCT LAUNCHES 42
3.2 RESTRAINTS 43
3.2.1 WEAK REIMBURSEMENT POLICIES 43
3.2.2 REGULATORY SCENARIO AND PRICING PRESSURE 43
3.3 OPPORTUNITIES 44
3.3.1 LOW BIOLOGIC PENETRATION 44
3.3.2 INCREASED COMPETITION LEADING TO HIGH INVESTMENTS IN R&D TO INNOVATE NEW PRODUCTS 44
3.3.3 INCREASING MERGERS AND ACQUISITIONS 45
3.3.4 EMERGING MARKET 45
3.4 CHALLENGES 46
3.4.1 SIDE EFFECTS 46
3.4.2 PRODUCT RECALL 46
3.4.3 HIGH COMPETITION 47
3.4.4 PENETRATION INTO THE SMALLER MARKETS 47
4 EXECUTIVE SUMMARY 48
5 PREMIUM INSIGHTS 52
6 GLOBAL RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET,
BY PRODUCT TYPE 54
6.1 OVERVIEW 55
6.2 SOLID 56
6.2.1 POWDER 57
6.2.2 OTHERS 57
6.3 SEMI-SOLID 57
6.3.1 CREAMS 59
6.3.2 GEL 59
6.3.3 OINTMENTS 59
6.3.4 PASTE 59
6.3.5 OTHERS 59
6.4 LIQUID 60
6.4.1 SOLUTION 61
6.4.2 EMULSION 61
6.4.3 SUSPENSION 61
6.4.4 LOTION 61
6.4.5 OTHERS 61
7 GLOBAL RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY APPLICATION 62
7.1 OVERVIEW 63
7.2 SKIN INFECTIONS 64
7.3 DERMATITIS 65
7.4 ANTIAGING 65
7.5 ACNE 66
7.6 HYPERPIGMENTATION 66
7.7 ROSACEA 67
7.8 SKIN CANCER 67
7.9 PSORIASIS 68
7.10 ONYCHOMYCOSIS 68
7.11 OTHERS 69
?
8 GLOBAL RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY CATEGORY 70
8.1 OVERVIEW 71
8.2 BRANDED 72
8.3 GENERIC 72
9 GLOBAL RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, BY GEOGRAPHY 73
9.1 OVERVIEW 74
9.2 NORTH AMERICA 77
9.2.1 U.S. 80
9.2.2 CANADA 83
9.2.3 MEXICO 85
9.3 EUROPE 87
9.3.1 GERMANY 91
9.3.2 FRANCE 93
9.3.3 ITALY 95
9.3.4 U.K. 97
9.3.5 SWITZERLAND 99
9.3.6 SPAIN 101
9.3.7 NETHERLANDS 103
9.3.8 RUSSIA 105
9.3.9 TURKEY 107
9.3.10 BELGIUM 109
9.3.11 REST OF EUROPE 111
9.4 ASIA-PACIFIC 112
9.4.1 JAPAN 116
9.4.2 CHINA 118
9.4.3 INDIA 120
9.4.4 SOUTH KOREA 122
9.4.5 AUSTRALIA 124
9.4.6 THAILAND 126
9.4.7 MALAYSIA 128
9.4.8 SINGAPORE 130
9.4.9 INDONESIA 132
9.4.10 PHILIPPINES 134
9.4.11 REST OF ASIA-PACIFIC 136
9.5 SOUTH AMERICA 137
9.5.1 BRAZIL 141
9.5.2 REST OF SOUTH AMERICA 143
?
9.6 MIDDLE EAST & AFRICA 144
9.6.1 SOUTH AFRICA 148
9.6.2 REST OF MIDDLE EAST & AFRICA 150
10 GLOBAL RX DERMATOLOGY TOPICAL DRUG DELIVERY MARKET, COMPANY LANDSCAPE 151
10.1 COMPANY SHARE ANALYSIS: GLOBAL 151
10.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 152
10.3 COMPANY SHARE ANALYSIS: EUROPE 153
10.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 154
11 COMPANY PROFILES 155
11.1 GLAXOSMITHKLINE 155
11.1.1 COMPANY OVERVIEW 155
11.1.2 REVENUE ANALYSIS 155
11.1.3 COMPANY SHARE ANALYSIS 156
11.1.4 GEOGRAPHICAL PRESENCE 156
11.1.5 PRODUCT PORTFOLIO 157
11.1.6 RECENT DEVELOPMENT 157
11.2 PFIZER INC. 158
11.2.1 COMPANY OVERVIEW 158
11.2.2 REVENUE ANALYSIS 158
11.2.3 COMPANY SHARE ANALYSIS 159
11.2.4 GEOGRAPHICAL PRESENCE 159
11.2.5 PRODUCT PORTFOLIO 160
11.2.6 RECENT DEVELOPMENTS 160
11.3 GALDERMA LABORATORIES, L.P. 161
11.3.1 COMPANY OVERVIEW 161
11.3.2 COMPANY SHARE ANALYSIS 161
11.3.3 GEOGRAPHICAL PRESENCE 162
11.3.4 PRODUCT PORTFOLIO 163
11.3.5 RECENT DEVELOPMENTS 163
11.4 LEO PHARMA A/S 164
11.4.1 COMPANY OVERVIEW 164
11.4.2 REVENUE ANALYSIS 164
11.4.3 COMPANY SHARE ANALYSIS 165
11.4.4 GEOGRAPHICAL PRESENCE 165
11.4.5 PRODUCT PORTFOLIO 166
11.4.6 RECENT DEVELOPMENTS 166
?
11.5 BAUSCH HEALTH COMPANIES INC. 167
11.5.1 COMPANY OVERVIEW 167
11.5.2 REVENUE ANALYSIS 168
11.5.3 COMPANY SHARE ANALYSIS 168
11.5.4 GEOGRAPHICAL PRESENCE 169
11.5.5 PRODUCT PORTFOLIO 169
11.5.6 RECENT DEVELOPMENT 171
11.6 ALLERGAN 172
11.6.1 COMPANY OVERVIEW 172
11.6.2 REVENUE ANALYSIS 172
11.6.3 COMPANY SHARE ANALYSIS 173
11.6.4 GEOGRAPHICAL PRESENCE 173
11.6.5 PRODUCT PORTFOLIO 174
11.6.6 RECENT DEVELOPMENTS 174
11.7 3M 175
11.7.1 COMPANY OVERVIEW 175
11.7.2 REVENUE ANALYSIS 175
11.7.3 GEOGRAPHICAL PRESENCE 176
11.7.4 PRODUCT PORTFOLIO 176
11.7.5 RECENT DEVELOPMENT 176
11.8 BAYER AG 177
11.8.1 COMPANY OVERVIEW 177
11.8.2 REVENUE ANALYSIS 177
11.8.3 GEOGRAPHICAL PRESENCE 178
11.8.4 PRODUCT PORTFOLIO 178
11.8.5 RECENT DEVELOPMENTS 179
11.9 CIPLA INC. 180
11.9.1 COMPANY OVERVIEW 180
11.9.2 REVENUE ANALYSIS 180
11.9.3 GEOGRAPHICAL PRESENCE 181
11.9.4 PRODUCT PORTFOLIO 181
11.9.5 RECENT DEVELOPMENT 181
11.10 HISAMITSU PHARMACEUTICAL CO., INC. 182
11.10.1 COMPANY OVERVIEW 182
11.10.2 REVENUE ANALYSIS 182
11.10.3 GEOGRAPHICAL PRESENCE 183
11.10.4 PRODUCT PORTFOLIO 183
11.10.5 RECENT DEVELOPMENT 183
?
11.11 KAKEN PHARMACEUTICAL CO.,LTD. 184
11.11.1 COMPANY OVERVIEW 184
11.11.2 REVENUE ANALYSIS 184
11.11.3 GEOGRAPHICAL PRESENCE 185
11.11.4 PRODUCT PORTFOLIO 185
11.11.5 RECENT DEVELOPMENTS 185
11.12 THE LUBRIZOL CORPORATION 186
11.12.1 COMPANY OVERVIEW 186
11.12.2 GEOGRAPHICAL PRESENCE 186
11.12.3 PRODUCT PORTFOLIO 187
11.12.4 RECENT DEVELOPMENT 187
12 RELATED REPORTS 188